Background and Purpose-Faster heart rate predicts higher mortality in coronary heart disease and acute ischemic stroke, but its prognostic significance in intracerebral hemorrhage remains uncertain. We aimed to determine the effect of admission heart rate on clinical and imaging outcomes in patients with intracerebral hemorrhage. Methods-A post hoc pooled analysis of the pilot and main phases of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT 1 and 2). Clinical outcomes were mortality and modified Rankin Scale score at 90 days; and imaging outcome was absolute growth in hematoma volume during the initial 24 hours. Patients were divided into 4 categories according to baseline heart rate (<65, 65-74, 75-84, and ≥85 bpm) and analyzed using multivariable adjusted models with the lowest heart rate group as the reference. Results-Of 3185 patients with available data, higher admission heart rate was associated with both mortality and worse modified Rankin Scale score: adjusted hazard ratio for heart rate (≥85 versus <65 bpm) 1.50 (95% confidence interval, 1.07-2.11) and adjusted odds ratio 1.33 (95% confidence interval, 1.08-1.63), respectively (both P-trend <0.05). There was no significant relationship between heart rate and absolute growth in hematoma volume (P-trend, 0.196). 
F aster heart rate predicts mortality and morbidity in a variety of cardiovascular diseases, independent of other factors. 1, 2 Although studies further suggest a relationship between heart rate and cognitive decline and poor functional outcome in patients with acute ischemic stroke, 3, 4 limited data exist on the significance of heart rate on outcome after intracerebral hemorrhage (ICH). Moreover, relationship between heart rate and hematoma growth, 5 which is a strong prognostic factor in patients with ICH, 6, 7 has not been studied. The objective of our study was to determine the association of baseline heart rate with mortality, functional outcome, and hematoma growth in patients with acute ICH.
Methods

Study Design and Participants
Data are from the pilot and main phases of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT 1 and 2), international, multicenter, open, blinded end point, randomized controlled trials, the details of which are described elsewhere. [8] [9] [10] [11] The studies combined included 3233 patients with spontaneous ICH within 6 hours of onset and elevated systolic blood pressure (150-220 mm Hg) randomly assigned to receive intensive (target systolic blood pressure, <140 mm Hg within 1 hour) or contemporaneous guideline-recommended (target systolic blood pressure, <180 mm Hg) BP-lowering therapy. Patients were excluded if they had a structural cerebral cause for the ICH, a high likelihood of death
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June 2016 within the next 24 hours (eg, massive ICH with midline shift of hemisphere or deep coma on presentation) or if early surgery to evacuate the ICH was planned. Written informed consent was obtained from each participant or his/her legal surrogate. The study protocol was approved by an appropriate ethics committee at each hospital site. The INTERACT studies are registered with ClinicalTrials.gov, numbers NCT00226096 and NCT00716079.
Procedures
Demographic and clinical characteristics were recorded at the time of enrollment. Participants' heart rate was recorded from an ECG monitor, or if unavailable, a recording was made using conventional procedures. The heart rate was only recorded before randomization (one measurement). Participants received computed tomographic (CT) scans according to standardized techniques at baseline, and a total of 1313 participants (346 in INTERACT1 and 967 in INTERACT2) had a repeat CT scan at 24 hours using the same procedure as the baseline scan. For each CT scan, hematoma volumes were calculated independently by trained neurologists who were blind to clinical and treatment data, and date and sequence of scan.
Outcomes
The primary and secondary clinical outcomes were mortality within 90 days and the shift of entire range of modified Rankin Scale (mRS) score at 90 days, respectively. Imaging outcome was the absolute increase in hematoma volume during initial 24 hours.
Statistical Analysis
For the purpose of the analyses, patients were categorized into 4 heart rate groups with approximately fourth cutoffs in consideration of recognizability (<65, 65-74, 75-84, and ≥85 bpm) . Baseline patient characteristics according to the heart rate categories were summarized as mean±SD or median (interquartile range) for continuous variables, and as number (%) for categorical variables, with comparisons made using Kruskal-Wallis or χ 2 tests. The association of admission heart rate and mortality within 90 days was examined in multivariable Cox regression models, adjusted for potential confounders including: age, female sex, China region, β-blocker use, antithrombotic use, log-transformed time from onset to randomization, systolic blood pressure, National Institutes of Health Stroke Scale score (divided by median, ≥11 versus <11), log-transformed baseline hematoma volume, hematoma location (deep versus nondeep), intraventricular extension of hematoma, trial, and intensive BP-lowering treatment. The proportionality of hazards assumption was tested by means of log-minus-log plots. The effects of heart rate on 90-day mRS shift (secondary clinical outcome) were analyzed using multivariable ordinal logistic regression model adjusted for the same variables as for the mortality analyses. The effect of admission heart rate on 24-hour hematoma growth was analyzed using ANCOVA and linear regression (with heart rate as continuous variable) adjusting for the same potential confounders as above. Sensitivity analyses with heart rate as a dichotomous variable (≥75 versus <75 bpm), continuous variables, and with precise fourth cutoffs were conducted for clinical outcomes. The robustness of our results was further tested by incorporating other confounders such as pulse pressure, Glasgow Coma Scale score, and change in hematoma volume in survival analysis models. 12 We also utilized propensity score methods to validate our findings. In addition, we identified factors associated with faster heart rate (≥75 bpm) using multivariable logistic regression. A standard level of significance (P<0.05) was used, and the data were reported with hazard ratios or odds ratios with 95% confidence intervals. All data were analyzed with the use of SAS software version 9.3 (SAS Institute, Cary, NC).
Results
Among 3233 participants of the pooled cohort from INTERACT studies, we included 3185 (99%) with available heart rate on admission (mean, 78±14 bpm) and information on mortality and mRS at 90 days in the present analyses. Baseline characteristics according to subgroups of heart rate are shown in Table 1 . Patients with higher heart rate had higher BP, more frequent intraventricular extension of hematoma, and were less likely to be enrolled in China, whereas patients with low heart rate were older, more often had a history of β-blocker and antithrombotics use, and had larger hematomas that were less likely to be in a lobar location. Table 2 and the Figure show the association between admission heart rate and mortality. Patients with elevated admission heart rate had a significant higher mortality, both in the crude and adjusted analyses. In Cox regression models, the risk of death was higher in the group with admission heart rate of 75 to 84 bpm (adjusted hazard ratio, 1.52; 95% confidence interval, 1.08-2.16) and of ≥85 bpm group (1.50; 95% confidence interval, 1.07-2.11) than in the group with heart rate <65 bpm (P-trend, 0.015; Table 2 ). Findings were similar in the sensitivity analyses with alternative cutoffs for heart rate, adjustment for Glasgow Coma Scale score and pulse pressure, and also in propensity score models (Tables I-III in the onlineonly Data Supplement) .
Relationship between heart rate and mRS at 90 days is shown in Table 3 . Risk of worse functional outcome defined by higher mRS scores was significantly increased in subjects with heart rate ≥85 bpm (adjusted odds ratios, 1.33; 95% confidence interval, 1.08-1.63) when compared with the reference group (heart rate, <65 bpm). Results were also confirmed in the analyses with heart rate as a dichotomized (high ≥75 versus low <75 bpm) or continuous variable, or variable with alternative cutoffs (Table 3; Table IV in the online-only Data Supplement). Propensity score-matched or propensity score-adjusted models also validated the finding of greater risk of unfavorable outcome in association with heart rate (≥75 bpm; all P<0.02; Table III in the onlineonly Data Supplement).
There was a nonsignificant trend between heart rate and absolute growth in hematoma volume in the model with heart rate divided into 4 groups (P trend, 0.196) , which seemed to be stronger in the model with heart rate divided into 2 groups (P trend, 0.065; Table 4 ). Insignificant results were found using multivariable linear regression analyses (P=0.410). Although no significant association was found between heart rate and hematoma volume growth, it seemed to confound the relationship between heart rate and 90-day mRS score in patients with available 24-hour CT data (n=1287; Table V in the online-only Data Supplement).
As shown in Table VI in the online-only Data Supplement, diastolic BP, nondeep hematoma location, and intraventricular extension were significantly associated with faster admission heart rate (≥75 bpm).
Discussion
The present pooled analysis of the 2 INTERACT studies demonstrates that higher heart rate on admission was associated with higher mortality and poorer functional outcome. No clear association was observed between heart rate and absolute growth in hematoma volume.
Most studies of the association of heart rate and in-hospital mortality have included patients with heart disease, such as acute coronary syndromes and heart failure. 13, 14 In terms of stroke, a single-center retrospective analysis of 1335 patients with acute ischemic stroke found that higher heart rate on admission was associated with higher in-hospital mortality. 4 Similarly, post hoc analysis from the Prevention Regimen for Effectively Avoiding Second Stroke (PRoFESS) study 3 found Intracerebral hemorrhage 270 (8) 43 (9) 63 (7) 79 (8) 85 (10) 0.358
Ischemic stroke 325 (10) 48 (10) 87 (10) 93 (10) 97 (11) 0.804
Acute coronary syndrome 93 (3) 21 (4) 25 (3) 23 (2) 24 ( (14) 66 (13) 116 (13) 133 (14) 137 (16) 0.507
Angiotensin-converting enzyme inhibitors 347 (11) 53 (11) 98 (11) 98 (10) 98 (11) 0.932
Angiotensin II receptor blockers 191 (6) 42 (8) 52 (6) 49 (5) 48 (5) 0.097 Diuretics 273 (9) 45 (9) 72 (8) 75 (8) 81 (9) 0.807 β-blockers 239 (8) 56 (11) 64 (7) 56 (6) 63 (7) 0.005 Antithrombotic therapy 364 (11) 74 (15) 89 (10) 95 (10) 106 (12) 0.040
Statin therapy 204 (6) 41 (8) 47 (5) 64 (7) 52 (6) (10) 33 (7) 71 (9) 78 (9) 100 (12) Basal ganglia or thalamus 2429 (83) 406 (85) 668 (85) 700 (82) 654 (81) Cerebellar 101 (3) 17 (4) 22 (3) 43 (5) 19 (2) Brain stem 90 (3) 19 (4) 22 (3) 24 (3) 25 (3) Intraventricular extension of hematoma 828 (28) 117 (24) 212 (27) 225 (27) a significant association between baseline heart rate and mortality, and lower heart rate was associated with less cognitive decline and better functional outcome in 20 165 patients with acute ischemic stroke. There is only 1 previous study of heart rate and outcomes in 108 patients with ICH, and it showed no significant relationship between heart rate and mortality or functional outcome. 15 These differences can be explained by the larger sample size of our analyses. Overall, the admission heart rate in our population was within normal range (mean heart rate, 78±14 bpm), yet our results were consistent when heart rate was categorized into both 2 and 4 groups, and also when used as a continuous variable, supporting the robustness of our results.
One possible reason for the link between higher heart rate and greater mortality and poorer function outcome is that high admission heart rate in ICH patients might reflect poor general health 16 and poor physiological condition such as dehydration, anemia, and comorbid heart disease, which are known predictors of outcome of stroke. [17] [18] [19] Also, heart rate is a marker of acute sympathetic adrenergic stress in response to severe ICH. Activation of sympathetic nervous system after stroke has been considered as a trigger of systemic immunodepression and subsequent increased risk of infection, 20 which is also one of important risk factors for death and disability after stroke.
Although severe ICH, as a preterminal event, is able to slow heart rate because of increased intracranial pressure (Cushing reflex), 21 significant relationships between lower heart rate and mortality were not observed in our study. The lack of association could be explained by INTERACT2 patients having predominantly small-to medium-sized ICH; those who had a high likelihood of death or early planned surgical evacuation of ICH being excluded from participation.
Our study showed no clear association of admission heart rate and hematoma growth, a strong predictor of outcome in ICH patients. 5, 22 Higher heart rate might reflect patient distress and could be associated with other parameters such as higher and unstable blood pressure that have been reported to be related to hematoma growth during the clinical course. 23, 24 In contrast to the main analyses, our subgroup analyses of patients with available 24-hour CT data (both with and without adjustment for hematoma growth) showed nonsignificant association between heart rate and 90-day mRS score. This is likely because of decreased statistical power of the subgroup analyses as the patient population was decreased by almost a half in comparison with the main analyses.
Our findings pose the question as to whether therapeutic reduction of heart rate is beneficial in the early phase after ICH. In experimental models, treatment with the selective sinus-node inhibitor ivabradine has reduced the risk of 
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ischemic injury, 25 whereas in patients with chronic heart failure, ivabradine reduced the risk of cardiovascular events. 26 However, another randomized trial of ivabradine in patients with stable coronary artery disease and left-ventricular systolic dysfunction 27 showed no such effects. Clinical evidence on effects of therapeutic reduction of heart rate on outcome in stroke patients with different pathophysiological mechanism from heart diseases is lacking.
Our analyses have some limitations. As the INTERACT database only reports 90-day outcomes, we cannot make any conclusions about long-term mortality and morbidity. Although we recognize that there are several previous studies that showed significant association between heart rate variability (which may be a surrogate for an unfavorable sympathetic dysfunction) and clinical outcomes, 22, 28, 29 we were unable to analyze heart rate changes after admission because of lack of data. The use of admission heart rate may present some inevitable confounding factors, such as instrumental error from different batches of ECG monitor, discrepancy from reading of heart rate fluctuation, and the emotional status of patients at the point of measurement. We were also unable to clarify the pathological mechanism underlying the observed admission heart rate among the patients, which can be diverse, ranging from poor physiological status and heart diseases, medication intake to autonomic imbalance. Nevertheless, our study was able to show that heart rate at a single time point in the acute setting could still be a simple and useful predictor of outcome in ICH. The results of this study also warrant future clinical investigations such as the prognostic effect of heart rate variability during hospitalization and changes in the choice of antihypertensive medication regime during the clinical course that were unfortunately not investigated in the present study because of a lack of relevant data. Exploring the therapeutic potential of heart rate modification by specific BP medications may guide the optimization of current treatment strategies to improve ICH outcome. Heart rate may be included as a variable of interest for the management of BP during acute phase of ICH in future trials. The 90-day mortality (12%) in the present analysis is lower than that previously reported (13%-61%) in a broader unselected ICH population, 30 as more severe cases (such as those with increased intracranial pressure and/or lower levels of Glasgow Coma Scale score) were excluded from participation in a randomized trial. Thus, these findings may not be generalizable. Furthermore, as these data are observational, they can only be used to demonstrate a strong association and cannot be interpreted to demonstrate causality.
In conclusion, faster admission heart rate was associated with increased mortality and worse functional outcome at 90 days in patients with acute ICH. (n=1242) 119 (10) 1 (Reference) 0.001 ≥75 bpm (n=1242) 170 (14) 1.50 (1.17-1.92)* mRS score † 1.19 (1.04-1.37)* 0.013 PS adjusted Death n (%) <75 bpm (n=1255) 121 (10) 1 (Reference) 0.002 ≥75 bpm (n=1649) 224 (14) 1.47 (1.16-1.86) mRS score † 1.17 (1.03-1.34) 0.018 OR indicates odds ratio; CI, confidence interval; PS, propensity score; pbm, beats per minute; and mRS, modified Rankin Scale. PS was derived from the multivariable logistic model with covariates of age, diastolic blood pressure, sex, National Institutes of Health Stroke Scale score (≥11 vs <11), baseline hematoma volume (≥15 vs <15 mL), hematoma location (deep vs non-deep), interventricular extension, trial (INTERACT1 vs INTERACT2), and intensive blood pressure lowering treatment. We used optimal matching 1:1 without replacement, with an initial caliper width matching algorithm that equates to 0.08 (20% of the SD of the logit of the PS). *Generalized estimating equations were used to test the effect of heart rate on death and mRS, accounting for matching in the PS-matched subpopulation.
†The mRS score ranges from 0 to 6 (0 indicates no symptom at all and 6 represents death). 0.175 CI indicates confidence interval; and pbm, beats per minute. *Adjusted for age, female sex, Chinese region, beta-blocker use, antithrombotic use, log-transformed hour from onset to randomization, systolic blood pressure, National Institutes of Health Stroke Scale score (≥11 vs <11), log-transformed baseline hematoma volume, hematoma location (deep vs non-deep), intraventricular extension, trial (INTERACT1 vs INTERACT2) and intensive blood pressure lowering treatment. † Adjusted for: age, female sex, Chinese region, beta-blocker use, antithrombotic use, log-transformed hour from onset to randomization, systolic blood pressure, National Institutes of Health Stroke Scale score (≥11 vs <11), log-transformed baseline hematoma volume, relative change in hematoma volume, hematoma location (deep vs non-deep), intraventricular extension, trial (INTERACT1 vs INTERACT2) and intensive blood pressure lowering treatment. 
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